Annals of oncology : official journal of the European Society for Medical Oncology · 1995
Secondary tumours following etoposide containing therapy for germ cell cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Boshoff C, Begent R H, Oliver R T, Rustin G J, Newlands E S, Andrews R, Skelton M, Holden L, Ong J
Аннотация
BACKGROUND: Reports have implied etoposide as the cause of secondary leukaemia in patients treated for germ cell cancer.
PATIENTS AND METHODS: Between 1979 and 1992, 679 male patients with germ cell cancer received etoposide containing chemotherapy.
RESULTS: Six of 679 patients developed acute myeloid leukaemia (relative risk 150; CI: 55-326). None of these patients had a primary mediastinal germ cell tumour and only 1 patient received previous radiotherapy. The median interval between the onset of cytotoxic treatment and the development of leukaemia was 27 months. The FAB M4 morphology was seen in 4 of 6 cases.
CONCLUSION: The benefit of etoposide containing protocols outweigh the risk of leukaemia in patients with intermediate or high risk disease, however in patients with good risk disease non-etoposide containing protocols should be explored.
PATIENTS AND METHODS: Between 1979 and 1992, 679 male patients with germ cell cancer received etoposide containing chemotherapy.
RESULTS: Six of 679 patients developed acute myeloid leukaemia (relative risk 150; CI: 55-326). None of these patients had a primary mediastinal germ cell tumour and only 1 patient received previous radiotherapy. The median interval between the onset of cytotoxic treatment and the development of leukaemia was 27 months. The FAB M4 morphology was seen in 4 of 6 cases.
CONCLUSION: The benefit of etoposide containing protocols outweigh the risk of leukaemia in patients with intermediate or high risk disease, however in patients with good risk disease non-etoposide containing protocols should be explored.
Предметные рубрики MeSH
Acute DiseaseAdolescentAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBleomycinCohort StudiesCyclophosphamideCytarabineDactinomycinDose-Response Relationship, DrugEtoposideGerminomaHumansLeukemia, MyeloidMaleMethotrexateMiddle AgedNeoplasms, Second PrimaryTesticular NeoplasmsVincristine